Ms. Sinclair is Senior Vice President, Corporate Operations at Arvinas. Ms. Sinclair has more than 25 years of biopharmaceutical experience, specializing in strategic operations, portfolio management, and new product development planning from preclinical to launch.
Prior to joining Arvinas, Ms. Sinclair served as Head of Corporate and Commercial Strategy at Rallybio, where she led strategic and operational planning, including market landscape assessments, sustainable pipeline analyses, approaches to portfolio growth, development of corporate goals and priorities, capability planning frameworks, and scenario planning.
Previously, Ms. Sinclair served as the Head of Program and Alliance Management for SpringWorks Therapeutics, where she was responsible for operational planning, life cycle strategy, and alliance collaborations. She also served as Vice President of R&D Strategy and Portfolio and Project Management at Alexion AstraZeneca Rare Disease, where she led generation of the long-term R&D strategy and built portfolio capabilities that informed investment in the pipeline and external opportunities in rare disease. Prior to Alexion, Ms. Sinclair was Vice President of Global R&D Portfolio and Performance at AstraZeneca, and she spent 18 years at Pfizer in various roles of increasing responsibility in R&D and commercial.
Ms. Sinclair began her career in marketing for the packaging industry and received a Bachelor of Arts in business administration with a concentration in marketing from the University of Vermont.